SCHEMBL4099332

SCHEMBL4099332

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(OCCC(F)(F)F)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 7/20 0.41
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
HIF1A Q16665 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
NPC1 O15118 1/20 0.35
TSHR P16473 1/20 0.35
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
HSD17B10 Q99714 2/20 0.34
AOC3 Q16853 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099269 0.92 CNR1 (0.48) CNR1MAOAMAOBHIF1ASMN1; SMN2
SCHEMBL4093553 0.88 MAOA (0.43) CNR1MAOAMAOBHIF1ASMN1; SMN2
SCHEMBL4104142 0.83 MAOA (0.42) CNR1MAOAMAOBHIF1ASMN1; SMN2
SCHEMBL5428510 0.82 CNR1 (0.38) CNR1HIF1AALDH1A1LMNAPDE4A
SCHEMBL4520786 0.81 CNR1 (0.39) CNR1HIF1ALMNAPDE4APDE4B
SCHEMBL4506382 0.80 CNR1 (0.39) CNR1HIF1ALMNAPDE4APDE4B
SCHEMBL5431917 0.80 CNR1 (0.39) CNR1MAOAMAOBHIF1APDE4A
SCHEMBL5431779 0.80 CNR1 (0.39) CNR1HIF1APDE4APDE4BPDE4C
SCHEMBL1993358 0.80 CNR1 (0.43) CNR1HIF1AALDH1A1LMNAPDE4A
SCHEMBL5434559 0.80 MAOA (0.39) CNR1MAOAMAOBHIF1APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233947-A1 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) MERCK SHARP & DOHME LTD. (GB) 2009-09-17 US claimed
US-20090233947-A1 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) MERCK SHARP & DOHME LTD. (GB) 2009-09-17 US disclosed
EP-1888586-A2 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) MERCK SHARP & DOHME LTD. (GB) 2008-02-20 EP disclosed
WO-2006120481-A2 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) MERCK SHARP & DOHME LIMITED (GB) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233947-A1 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) TRPV1, TRPV2, TRPV3 CNR1 30/4885MAOA 3635/4885MAOB 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.